Deciphera Pharmaceuticals, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $163.4M | $134.0M | $96.1M | $42.1M | $25.0M | $0 |
| Operating income | −$211.0M | −$182.7M | −$300.1M | −$271.2M | −$200.7M | −$104.1M |
| Net income | −$194.9M | −$178.9M | −$300.0M | −$266.5M | −$192.3M | −$99.9M |
| Total assets | $473.6M | $454.0M | $429.5M | $642.4M | $622.4M | $315.6M |
| Total liabilities | $122.7M | $112.3M | $124.8M | $98.8M | $75.9M | $35.6M |
| Equity | $350.9M | $341.7M | $304.7M | $543.7M | $546.5M | $280.0M |
| EPS (diluted) | $-2.29 | $-2.37 | $-5.16 | $-4.78 | — | — |
| Shares out. | 75.9M | 58.6M | 57.6M | 55.6M | 38.2M | 32.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −129.1%
- Net margin
- −119.3%
- Return on equity
- −55.6%
- Return on assets
- −41.2%
- Return on capital (ROCE)
- −56.5%
- Liabilities / assets
- 25.9%
- Debt / equity
- 0.35×
- Book value / share
- $4.62
- Revenue growth (YoY)
- 21.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -5.93distress
- Accruals / assets
- −10.2%clean
- Beneish M-Score
- -2.41normal
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2021-09-01A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
- Phase 3Active Not Recruitingreadout ~2023-08-10Study of Vimseltinib for Tenosynovial Giant Cell Tumor
- Phase 1Recruitingreadout ~2026-06Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
- Phase 1/2Active Not Recruitingreadout ~2026-07Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
- Phase 1/2Recruitingreadout ~2027-03A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
- Phase 3Active Not Recruitingreadout ~2027-12A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
- Phase 1/2Recruitingreadout ~2028-05A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
- Phase 1Recruitingreadout ~2029-02Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventJun 11, 2024
- Entered a material agreement · Other material eventApr 29, 2024
- Results of operationsFeb 6, 2024
- Results of operations · Other material eventJan 8, 2024
- Results of operations · Other material eventOct 30, 2023
- Results of operationsAug 9, 2023
- Director / officer changeAug 3, 2023
- Shareholder voteJun 22, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.